Cyclerion Therapeutics Inc Cash Flow Conversion Efficiency
Cyclerion Therapeutics Inc cash flow conversion efficiency. Based on the latest financial reports, Cyclerion Therapeutics Inc (CYCN) has a cash flow conversion efficiency ratio of -0.282x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.43 Million) by net assets ($5.09 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Cyclerion Therapeutics Inc (2016–2025)
Cash flow conversion efficiency of Cyclerion Therapeutics Inc from 2016 to 2025. This chart illustrates how Cyclerion Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View CYCN share price today for real-time trading data and today's change.
Cyclerion Therapeutics Inc Cash Flow Conversion Ratio Explained
Cyclerion Therapeutics Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Cyclerion Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Cyclerion Therapeutics Inc ranked by their cash flow conversion efficiency. Also see market cap of Cyclerion Therapeutics Inc for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
The Income & Growth VCT
LSE:IGV
|
-0.016x |
|
Laxmi Cotspin Limited
NSE:LAXMICOT
|
0.025x |
|
JPMorgan China Growth & Income PLC
LSE:JCGI
|
0.008x |
|
Afentra PLC
LSE:AET
|
0.330x |
|
BioNexus Gene Lab Corp Common stock
NASDAQ:BGLC
|
-0.181x |
|
Invion Ltd
AU:IVX
|
-0.163x |
|
Brown Advisory US Smaller Companies PLC
LSE:BASC
|
-0.002x |
|
Majedie Investments
LSE:MAJE
|
0.008x |
Annual Cash Flow Conversion Efficiency for Cyclerion Therapeutics Inc (2016–2025)
The table below shows the annual cash flow conversion efficiency of Cyclerion Therapeutics Inc from 2016 to 2025. Review CYCN cash flow after capex ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $9.09 Million | $-3.31 Million | -0.365x | +25.50% |
| 2024-12-31 | $8.85 Million | $-4.33 Million | -0.490x | +73.99% |
| 2023-12-31 | $11.29 Million | $-21.25 Million | -1.882x | +51.56% |
| 2022-12-31 | $10.45 Million | $-40.61 Million | -3.885x | -413.35% |
| 2021-12-31 | $48.25 Million | $-36.52 Million | -0.757x | +37.88% |
| 2020-12-31 | $59.49 Million | $-72.49 Million | -1.218x | -16.50% |
| 2019-12-31 | $97.73 Million | $-102.22 Million | -1.046x | -111.20% |
| 2018-12-31 | $-10.45 Million | $-97.50 Million | 9.335x | -1.53% |
| 2017-12-31 | $-8.57 Million | $-81.22 Million | 9.480x | +28.52% |
| 2016-12-31 | $-6.76 Million | $-49.87 Million | 7.377x | -- |
About Cyclerion Therapeutics Inc
As of September 8, 2026, Cyclerion Therapeutics, Inc. was acquired by Korsana Biosciences, Inc. in a reverse merger transaction. Cyclerion Therapeutics, Inc., a biopharmaceutical company, engages in the development of treatments for serious diseases serious diseases with novel sGC stimulators in both the central nervous system (CNS) and the periphery. The company is developing Olinciguat, an oral… Read more